+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
531015 VENMAX

Venmax Drugs & Pharmaceuticals Share Price

 

 

Venmax Drugs & Pharmaceuticals live price: ₹20.1. It opened at ₹20 vs previous close ₹20; intraday high/low: ₹21/₹20. The 50 & 200 DMA stand at ₹22.95/₹24.48.

Venmax Drugs & Pharmaceuticals Performance

  • Today's Low
  • ₹20
  • Today's High
  • ₹21
  • 52 Week Low
  • ₹19
  • 52 Week High
  • ₹37
  • Open Price₹20
  • Previous Close₹20
  • Volume4,056
  • 50 DMA₹22.95
  • 100 DMA₹24.11
  • 200 DMA₹24.48

Venmax Drugs & Pharmaceuticals Chart

Investment Returns

  • Over 1 Month -13.4%
  • Over 3 Month -19.11%
  • Over 6 Month -29.99%
  • Over 1 Year -26.91%

Smart Investing Starts Here Start SIP with Venmax Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Venmax Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 87.8
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 18
  • P/B Ratio
  • 1.6
  • Average True Range
  • 2.28
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.01
  • RSI
  • 40.54
  • MFI
  • 8.98

Venmax Drugs & Pharmaceuticals Financials

Venmax Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹20.10
+ 0.23 (1.16%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹21.40
  • 50 Day
  • ₹23.00
  • 100 Day
  • ₹24.10
  • 200 Day
  • ₹24.50

Resistance and Support

20.29 Pivot Speed
  • R3 22.14
  • R2 21.56
  • R1 20.87
  • S1 19.60
  • S2 19.02
  • S3 18.33

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Venmax Dg.And Pharms. has an operating revenue of Rs. 8.03 Cr. on a trailing 12-month basis. An annual revenue growth of 340% is outstanding, Pre-tax margin of 3% needs improvement, ROE of 1% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 8 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venmax Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-14 Audited Results
2026-02-07 Quarterly Results
2025-11-12 Quarterly Results
2025-09-02 Amalgamation & A.G.M.
2025-08-16 Others Inter alia, to consider and approve 1. Allotment of Equity Shares pursuant to conversion of Convertible Equity Share Warrants.

Venmax Drugs & Pharmaceuticals Shareholding Pattern

13.8%
66.29%
19.91%

Venmax Drugs & Pharmaceuticals FAQs

Venmax Drugs & Pharmaceuticals share price is ₹20 As on 21 June, 2026 | 12:12

The Market Cap of Venmax Drugs & Pharmaceuticals is ₹17.7 Cr As on 21 June, 2026 | 12:12

The P/E ratio of Venmax Drugs & Pharmaceuticals is 87.8 As on 21 June, 2026 | 12:12

The PB ratio of Venmax Drugs & Pharmaceuticals is 1.6 As on 21 June, 2026 | 12:12

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23